Compare General Dynamics Corporation (GD) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Tenet Healthcare Corporation — how do they compare? General Dynamics Corporation trades at $331.7 (market cap $89.26B), while Tenet Healthcare Corporation trades at $265.57 (market cap $20.98B). The key difference: General Dynamics Corporation is far larger — about 4.3× Tenet Healthcare Corporation's market cap, and General Dynamics Corporation pays a 1.93% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Tenet Healthcare Corporation for 15 Days on average.
| GD | THC | |
|---|---|---|
Market Cap | $89.26B | $20.98B |
Volume | 1,496,273 | 428,008 |
Sector | Industrials | Health |
52-Week High | $395.97 | $280.77 |
52-Week Low | $312.53 | $161.37 |
Typical Hold Time | 85 Days | 15 Days |
Enterprise Value | $94.40B | $32.06B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.77, up 1.57% today, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $4.14. Revenue grew to $52.55B in 2025, and net income margin improved to 8.18%. Analyst consensus is bullish with a $420.57 price target, supported by defense budget tailwinds and dividend stability.
The outlook remains positive due to robust Pentagon spending and contract visibility, though technical weakness near support at $320 poses short-term risk. Long-term growth is underpinned by submarine and vehicle demand, but investors face volatility from defense budget cycles and geopolitical uncertainties. The stock offers value with a P/E of 20.12 and a sustainable dividend.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
